Mediwound (MDWD) has released an update.
MediWound Ltd. reported positive outcomes from the NEXT protocol, showcasing the safety and effectiveness of their NexoBrid product in removing eschar and substantially reducing surgical procedures for burn patients. The program has verified NexoBrid’s rapid debridement capability in both adults and children, with the vast majority achieving complete eschar removal without the need for surgical excision. These results support NexoBrid’s integration into standard burn care protocols.
For further insights into MDWD stock, check out TipRanks’ Stock Analysis page.
